In conclusion, an enhanced binding of morpholino-[124/131I]IPQA derivatives to the ATP binding site of mutant kinase of L858R or E746-A750 del EGFR mutant warrants that PET imaging with morpholino-[124I]IPQA has a potential for identification of tumors with high EGFR kinase activity in NSCLC and for the monitoring or selection of individual therapies with EGFR inhibitors. Here, EGFR is linked to non-small cell lung carcinoma.